Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yusuke Noda

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Frontiers in Immunology|October 13, 2025
Real-world outcomes of immune checkpoint inhibitor-based combination therapy in older adult patients with metastatic renal cell carcinoma: a multi-center, retrospective analysisHiroaki Ikoma, Shuzo Hamamoto, Yoshihiko Tasaki, et al.
Oncology|July 2, 2024
Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in Metastatic Urothelial CarcinomaTeruki Isobe, Taku Naiki, Yosuke Sugiyama, et al.
International Journal of Clinical Oncology|October 11, 2021
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysisTeruki Isobe, Taku Naiki, Yosuke Sugiyama, et al.
Oncology|June 27, 2022
Survival Outcome after Reduced-Port Laparoscopic Radical Cystectomy for Bladder Cancer: Long-Term Follow-Up AnalysisYusuke Noda, Taku Naiki, Yosuke Sugiyama, et al.
In Vivo (Athens, Greece)|June 27, 2025
Effect of Pembrolizumab on Lymph Node Dissection in Patients Who Experienced Bladder Cancer Recurrence Following Radical CystectomyYoshihiko Tasaki, Takashi Nagai, Taku Naiki, et al.
Cancers|May 11, 2024
C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective StudyToshiharu Morikawa, Taku Naiki, Yosuke Sugiyama, et al.
Oncology|January 23, 2023
GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial CarcinomaYosuke Sugiyama, Taku Naiki, Yoshihiko Tasaki, et al.
Cancers|May 4, 2026
Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-UpHiroaki Ikoma, Shuzo Hamamoto, Yoshihiko Tasaki, et al.
Cancer Medicine|July 1, 2026
Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder CancerKunihiro Odagiri, Yoshihiko Tasaki, Taku Naiki, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 7, 2023
Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinomaNami Tomiyama, Yoshihiko Tasaki, Shuzo Hamamoto, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|October 13, 2025
Real-world outcomes of immune checkpoint inhibitor-based combination therapy in older adult patients with metastatic renal cell carcinoma: a multi-center, retrospective analysisHiroaki Ikoma, Shuzo Hamamoto, Yoshihiko Tasaki, et al.
Oncology|July 2, 2024
Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in Metastatic Urothelial CarcinomaTeruki Isobe, Taku Naiki, Yosuke Sugiyama, et al.
International Journal of Clinical Oncology|October 11, 2021
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysisTeruki Isobe, Taku Naiki, Yosuke Sugiyama, et al.
Oncology|June 27, 2022
Survival Outcome after Reduced-Port Laparoscopic Radical Cystectomy for Bladder Cancer: Long-Term Follow-Up AnalysisYusuke Noda, Taku Naiki, Yosuke Sugiyama, et al.
In Vivo (Athens, Greece)|June 27, 2025
Effect of Pembrolizumab on Lymph Node Dissection in Patients Who Experienced Bladder Cancer Recurrence Following Radical CystectomyYoshihiko Tasaki, Takashi Nagai, Taku Naiki, et al.
Cancers|May 11, 2024
C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective StudyToshiharu Morikawa, Taku Naiki, Yosuke Sugiyama, et al.
Oncology|January 23, 2023
GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial CarcinomaYosuke Sugiyama, Taku Naiki, Yoshihiko Tasaki, et al.
Cancers|May 4, 2026
Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-UpHiroaki Ikoma, Shuzo Hamamoto, Yoshihiko Tasaki, et al.
Cancer Medicine|July 1, 2026
Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder CancerKunihiro Odagiri, Yoshihiko Tasaki, Taku Naiki, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 7, 2023
Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinomaNami Tomiyama, Yoshihiko Tasaki, Shuzo Hamamoto, et al.
Pageof 5